{
    "clinical_study": {
        "@rank": "92397", 
        "arm_group": [
            {
                "arm_group_label": "patient"
            }, 
            {
                "arm_group_label": "healthy volunteers"
            }
        ], 
        "brief_summary": {
            "textblock": "Lupus disease is characterized by the production of pathogenic autoantibodies, which\n      participate in end-organ damages. The phenotype of B cells producing the pathogenic\n      autoantibodies in lupus patients is today unknown. Antinucleosome antibodies are\n      characteristic of lupus disease.This project proposes to detect antinucleosome B cells in\n      lupus patients and to analyse their phenotype and their frequency."
        }, 
        "brief_title": "Anti-nucleosome B Lymphocytes in Lupus", 
        "completion_date": {
            "#text": "July 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Systemic Lupus Erythematosus With or Without Clinical Activity", 
        "condition_browse": {
            "mesh_term": "Lupus Erythematosus, Systemic"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria for SLE patients:\n\n        SLE patient : diagnostic based on ACR criteria\n\n          -  SLE patient producing seric anti-nucleosome antibodies (ELISA)\n\n          -  SLEDAI-2K activity score : inferior to 5 for quiescent patients, superior to 8 since\n             at least 2 months for active patients\n\n        Exclusion criteria for SLE patients:\n\n        -- Other autoimmune diseases than SLE- Induced lupus\n\n          -  Treatment with corticosteroids >10mg/d (prednisone) for  quiescent patients\n\n          -  Treatment with corticosteroids >20mg/d (prednisone) for  active patients\n\n          -  Oral immunosuppressive treatment during the last 6 months (methotrexate,\n             azathioprine, ciclosporine, mycoph\u00e9nolate mof\u00e9til) for all patients,  treatment\n             during the last year with  cyclophosphamide or monoclonal antibodies (rituximab,\n             belimumab) for pour quiescent patients\n\n          -  Disease which can modify B and T lymphocyte functions: primary immune deficiencies,\n             evolutive infections, chronic viral infection (VIH in particular), chemotherapy or\n             neoplasm antecedent"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "60 Years", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "lupus patient and healthy volunteers"
            }
        }, 
        "enrollment": {
            "#text": "90", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 25, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01889654", 
            "org_study_id": "5543"
        }, 
        "intervention": {
            "arm_group_label": [
                "patient", 
                "healthy volunteers"
            ], 
            "intervention_name": "Venous blood sampling", 
            "intervention_type": "Other"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "January 14, 2014", 
        "location": {
            "contact": {
                "last_name": "Pauline Soulas Sprauel, M"
            }, 
            "facility": {
                "address": {
                    "city": "Strasbourg", 
                    "country": "France", 
                    "state": "Bas Rhin", 
                    "zip": "67091"
                }, 
                "name": "Les H\u00f4pitaux Universitaires de Strasbourg"
            }, 
            "investigator": [
                {
                    "last_name": "Anne-Sophie KORGANOW, MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Catherine MUTTER, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Pauline Soulas Sprauel, MD", 
                    "role": "Principal Investigator"
                }
            ], 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_groups": "2", 
        "official_title": "Analysis of Frequency and Phenotype of Anti-nucleosome B Lymphocyte in Systemic Lupus", 
        "overall_contact": {
            "email": "pauline.soulas@ibmc-cnrs.unistra.fr", 
            "last_name": "Pauline Soulas-Sprauel, MD"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "July 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "all cause mortality", 
            "safety_issue": "No", 
            "time_frame": "1 year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01889654"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "University Hospital, Strasbourg, France", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University Hospital, Strasbourg, France", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "January 2014"
    }
}